ERIC ROHREN to Neoplasm Staging
This is a "connection" page, showing publications ERIC ROHREN has written about Neoplasm Staging.
Connection Strength
0.357
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.121
-
PET/Computed Tomography and Patient Outcomes in Melanoma. PET Clin. 2015 Apr; 10(2):243-54.
Score: 0.092
-
Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978.
Score: 0.026
-
State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. Radiol Clin North Am. 2016 May; 54(3):581-96.
Score: 0.025
-
Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):906-14.
Score: 0.021
-
PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8.
Score: 0.019
-
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
Score: 0.019
-
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
Score: 0.018
-
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
Score: 0.017